Form 4: Fairmount Funds Plans ZBIO Stock Purchase

Fairmount Funds Management LLC and related entities plan to acquire 150,000 shares of Zenas BioPharma common stock at $20 per share on March 31, 2026, under a Rule 10b5-1 plan.

Summary

• Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Tomas Kiselak, and Peter Harwin are reporting persons for this transaction.
• They plan to acquire 150,000 shares of Zenas BioPharma, Inc. (ZBIO) common stock.
• The transaction is scheduled for March 31, 2026, at a price of $20 per share.
• This purchase is being made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following the transaction, Fairmount Healthcare Fund II L.P. will indirectly own 2,359,025 shares.
• Tomas Kiselak, a director of ZBIO, is also a Managing Member of Fairmount Funds Management LLC.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal. A significant insider purchase by a 10% owner and director, especially under a Rule 10b5-1 plan, demonstrates high confidence in the company's future value and strategic direction.

Positives

• A significant insider purchase of 150,000 shares indicates strong confidence in Zenas BioPharma's future prospects from a major institutional investor and director.
• The purchase price of $20 per share establishes a clear valuation point for this substantial insider investment.
• The transaction is pre-planned under Rule 10b5-1(c), suggesting a strategic, long-term investment approach rather than opportunistic timing.

Future Outlook

The planned acquisition of Zenas BioPharma shares by Fairmount Funds Management LLC and related entities on March 31, 2026, suggests a positive long-term outlook from these significant shareholders and directors, as indicated by their pre-arranged Rule 10b5-1 trading plan.

Management Comments

• Fairmount Funds Management LLC is the investment manager for Fairmount Healthcare Fund II L.P.
• The managers of Fairmount are Peter Harwin and Tomas Kiselak.
• Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
• Fairmount may be deemed a director by deputization of Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is also a Managing Member of Fairmount.

Industry Context

StockSavvy.ai notes that insider purchases, especially by significant shareholders and directors, often signal strong internal confidence in a company's prospects. In the biopharma sector, such investments can be particularly impactful, as they may reflect optimism regarding pipeline developments, clinical trial outcomes, or strategic positioning, differentiating Zenas BioPharma from peers facing capital constraints or uncertain futures.

Comparison to Industry Standards

• Insider buying, particularly by institutional investors like Fairmount Funds, is generally viewed positively, aligning with best practices for demonstrating commitment to a company's success.
• The use of a Rule 10b5-1 plan for this transaction is a standard practice for insiders to execute trades in a pre-planned, compliant manner, mitigating concerns about opportunistic trading.
• Compared to other biopharma companies where insider selling might raise red flags, this significant purchase by a 10% owner and director suggests a bullish stance on Zenas BioPharma's valuation and future potential.

Related Party Transactions

• Fairmount Funds Management LLC, as the investment manager for Fairmount Healthcare Fund II L.P., is acquiring shares in Zenas BioPharma, Inc., where Tomas Kiselak, a Managing Member of Fairmount, also serves as a director.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of future stock performance and management's belief in the company's value.
• Creditors might perceive increased stability and confidence in the company's long-term viability due to significant insider investment.

Next Steps

• Completion of the planned acquisition of 150,000 common shares on March 31, 2026.

Key Dates

Recommendation

The planned acquisition of 150,000 shares by a significant institutional investor and director at a fixed price of $20 per share, executed under a Rule 10b5-1 plan, signals strong conviction in Zenas BioPharma's valuation and future prospects. This insider buying activity suggests that key stakeholders believe the stock is undervalued or poised for growth, making it an attractive 'buy' for seasoned investors.

Keywords

Zenas BioPharma, ZBIO, Fairmount Funds Management, Insider Trading, Form 4, Stock Purchase, Rule 10b5-1, Biopharma, Healthcare Investment